NXPL · NextPlat Corp
The latest filing states the doubt was alleviated.
“These conditions raised substantial doubt about the Company's ability to continue as a going concern for the twelve months following the issuance of these Condensed Consolidated Financial Statements. Management has evaluated its plans to mitigate these conditions. These plans include expanding the Company's long-term care pharmacy operations, increasing 340B contract pharmacy revenue, developing additional institutional medication fulfillment contracts, and implementing identified operational efficiencies. For the six months ended June 30, 2026, operating loss decreased to approximately $1.2 million from $3.9 million, and cash used in operating activities decreased to approximately $1.5 million from $3.1 million. As of June 30, 2026, the Company had cash of approximately $11.9 million and $3.8 million of remaining availability under the ATM Program. Based on these results, management's projections of operating results and cash flows for the twelve months following issuance, and the Company's liquidity position, management has concluded that its plans, which are probable of being effectively implemented and probable of mitigating the relevant conditions, alleviate the substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Aug 13, 2026TL;DR. NextPlat posted a clear Q2 2026 inflection, with revenue rising ~21% sequentially to $11.9M, a record ~40% gross margin, and an ~87% reduction in net loss to $144K, while management guided to positive earnings for the remainder of 2026 and pursued selective Florida pharmacy acquisitions.
- + Sequential quarterly revenue grew ~21% to $11.9M in Q2 2026. new
- + Net loss attributable to common stockholders decreased ~92% year-over-year to ~$0.1M (~$0.05/share). new
- + Consolidated gross margin reached a record ~40%, up from 22% in the prior-year quarter. new
- + Contracted pharmacy revenue grew 136% YoY to ~$2.2M, driven by 340B and medication fulfillment contracts. new
- + E-commerce revenue grew ~27% sequentially to ~$4.1M with improved margin and government/military sales surpassing $1.75M. new
- + Balance sheet strengthened with ~$11.9M cash, ~$14.2M working capital, and no material unsecured debt.
- − Total pharmacy prescription revenue declined to ~$5.6M from ~$8.2M YoY due to lower payer reimbursement rates and payer mix. new
- − Total operating expenses rose slightly to ~$4.8M from ~$4.7M, driven by a $0.5M one-time increase in professional fees. new
- − Ongoing lawsuit remains unresolved, with disclosure pending in the upcoming Form 10-Q. new
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Gross margin for e-Commerce Operations | 27% | second quarter of 2026 | — |
| Gross margin in the Healthcare Operations segment | 46% | second quarter of 2026 | — |
| Overall gross margin | 40% | second quarter ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Software - Application — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NXPL
this stock
NextPlat Corp
|
$24.54M | — | +2.5% | — | 0.1% |
|
QH
QUHUO Ltd
|
$314.26B | +228.7% | +59.7% | — | 0.0% |
|
SAP
Sap SE
|
$264.29B | -4.2% | — | — | 0.4% |
|
SHOP
Shopify Inc.
|
$223.21B | +8.3% | +30.1% | 116.4 | 1.6% |
|
CRM
Salesforce, Inc.
|
$198.98B | -8.7% | +25.9% | 22.1 | 4.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NXPL | -5.5% | -5.4% | +34.7% | -0.8% | +62.5% |
| SPY | +0.5% | +0.7% | +7.6% | +1.4% | +13.4% |
| vs SPY | -6.0% | -6.1% | +27.2% | -2.2% | +49.1% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.